Results from a phase 1/2 clinical trial (NCT05099172) show the safety and efficacy of sevabertinib (BAY2927088) in patients ...

Amtagvi monotherapy achieved a 25.6% objective response rate and 71.8% disease control rate in NSCLC patients without ...

The use of immunotherapy in patients with various types of cancer has led to dramatic increases in survival. Increased median ...

IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical ...

Last month, IceCure Medical’s tumor-freezing technology won FDA approval for treating early-stage breast cancer. Now, the Israel-based medtech is touting a new study showing its procedure combined ...

5-year overall survival (OS) rate for stereotactic body radiation ... body radiation therapy plus cryoablation using liquid nitrogen for stage I non-small cell lung cancer with tumors =2 cm" in the ...

October brought several updates in the lung cancer field, ranging from notable trial results to patient-centered perspectives ...

Lung06 Phase 3 Trial of ENHERTU Initiated as First-Line Therapy in Patients with HER2 Overexpressing Metastatic NSCLC ...

Outstanding measure of efficacy relative to high-risk cancers with limited treatment optionsCHICAGO, (GLOBE NEWSWIRE) -- MAIA ...

A new study finds that combining the COVID vaccine with immunotherapy may nearly double cancer survival rates — patients ...

According to the latest statistics from the Ministry of Data and Statistics, 21.9% of cancer-related deaths are attributed to ...

Camu camu, containing castalagin, was safe in combination with immune checkpoint inhibitors for melanoma and NSCLC patients, with manageable adverse events. The melanoma cohort showed a 13% ORR in ...